Business
Sareum: Final Results for Year Ended 30 June 2021
Sareum: Final Results for Year Ended 30 June 2021.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0181Q\n Sareum Holdings PLC\n 25 October 2021\n \n \n \n \n SAREUM HOLDINGS PLC\n \n \n (\"Sareum\" or \"the Company\")\n \n FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2021\n \n Cambridge, UK, 25 October 2021\n - \n Sareum Holdings plc (AIM: SAR), \n the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of autoimmune diseases and cancer, announces\n \n its audited results for the year ended 30 June 2021.\n \n \n The Company will be holding a presentation to investors on Tuesday, 2 November 2021 at 11.00 a.m. via the Investor Meet Company platform - please click on this link to register to attend: \n \n \n \n https://www.investormeetcompany.com/sareum-holdings-plc/register-investor\n \n \n \n The Company expects to publish its Annual Report and Accounts, along with the Notice of the Company's Annual General Meeting, in November 2021.\n \n \n OPERATIONAL HIGHLIGHTS (including post-period updates)\n \n \n Proprietary Programmes - Selective TYK2/JAK1 Inhibitors\n \n \n SDC-1801 (autoimmune diseases and severe Covid-19) \n \n \n • Progress made advancing SDC-1801 with preclinical phase nearing completion\n \n \n •Development of improved drug product underway for first clinical studies; decision made to develop potentially higher-value capsule formulations rather than orally dosed solutions or suspensions means this stage is expected to complete during H1 2022\n \n \n • Consultants appointed to assist in developing the plan for initial clinical studies \n \n \n •\n Exploratory Clinical Trial Application (\"CTA\") now expected to be filed mid-2022 owing to the additional time needed to manufacture capsule drug product, and subject to successful completion of final toxicity and safety studies\n \n \n •\n First clinical studies targeted to begin shortly thereafter, subject to drug product supply, gaining the requisite approvals and additional funding\n \n \n • Promising cellular and in-vivo results from completed UK Research & Innovation (\"UKRI\") -funded research project suggest therapeutic potential of SDC-1801 in severe phase Covid-19\n \n \n • Encouraging preclinical data reported with Sareum's TYK2/JAK1 inhibitors in systemic lupus erythematosus disease models - studies conducted by co-development partner SRI International under ...